THE SMARTER E EUROPE 2022: INNOVATIVE SOLUTIONS FOR THE ENERGY TRANSITION AND SECURITY OF SUPPLY
30.3.2022 11:05:00 EEST | Business Wire | Press release
Independence from fossil fuels is key for climate protection – and is of relevance for security policy in light of Russia’s war in Ukraine. Europe must make enormous strides towards renewable energies in order to achieve climate targets and ensure security of supply. At The smarter E Europe – Europe's largest platform for the energy industry – 1,450 exhibitors will present innovative products and solutions to 50,000 trade visitors over an exhibition area of 132,000 m2 from May 11 to 13 in Munich.
Rising electricity and gas prices and dependence on Russian gas are giving the energy transition a tailwind. The transition is urgently needed, and possible: photovoltaics (PV) have been successful for two decades, the energy storage industry has been gaining traction for ten years, and electromobility and charging infrastructure are booming. The solutions for an independent energy supply are ready - now it is time to deploy them sustainably. Renewable energy, decentralization, digitalization, sector coupling, smart and networked energy systems as well as smart charging systems and e-mobility are the focus of The smarter E Europe 2022. Another key topic is green hydrogen. At the exhibition, the “Green Hydrogen Forum & Expo” will provide important impetus for bringing hydrogen, fuel cells, electrolysis and power-to-gas technology to the markets at an accelerated pace.
Focus on energy and mobility transition
The smarter E Europe includes four energy exhibitions: Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe. At Intersolar Europe, companies will present cell concepts and modules as well as inverters and solutions for building-integrated PV, agri-PV (simultaneous land use for agriculture and electricity production using PV systems) and floating PV systems. However, solar power alone does not make an energy transition; rather, what is needed is integrated solutions for a full supply of renewable energy 24/7 and across all seasons. The focus of ees Europe 2022 will therefore be on storage technologies, and in particular battery storage and green hydrogen.
Renewable energy and interconnected energy systems are closely linked to the goal of climate neutrality and the need to reassess security of supply. EM-Power Europe will therefore present smart grid solutions, smart buildings and neighborhoods, and digital business models for municipal utilities and energy providers. Power2Drive Europe will demonstrate the interconnectedness of new energies and mobility and explore everything related to the mobility of the future. This includes in particular intelligent charging solutions, vehicle-to-grid technologies, solar charging infrastructure and e-vehicles.
On May 10 – the day before the exhibition opens – visitors to the accompanying specialist conferences will discover all facets of the new energy world. In the evening, the industry innovation drivers will be honored with the Intersolar AWARD, the ees AWARD and The smarter E AWARD. Exhibition forums and workshops will bring visitors together with key industry representatives.
The smarter E Europe, which encompasses the four individual exhibitions will take place from May 11–13, 2022, at Messe München.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005519/en/
Contact information
Contact:
Solar Promotion GmbH | PO Box 100 170 | 75101 Pforzheim
Horst Dufner | Tel.: +49 7231 58598-0 | Fax: +49 7231 58598-28
dufner@solarpromotion.de
Press contact:
fischerAppelt, relations | Otl-Aicher-Str. 64 | 80807 Munich
Felizia Rein| Tel. +49 89 74 74 66 40
felizia.rein@fischerappelt.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom